Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation. [PDF]
Xie M +7 more
europepmc +1 more source
Comparative incidence of endophthalmitis after intravitreal dexamethasone implant versus anti-VEGF injections: a retrospective study. [PDF]
Zabaneh ID, Dunn T, Dunn K, Williams P.
europepmc +1 more source
Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization. [PDF]
Tong Y +8 more
europepmc +1 more source
Biomarkers of Diabetic Macular Edema on Optical Coherence Tomography After Cataract Surgery. [PDF]
Tran T +4 more
europepmc +1 more source
Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit
To investigate whether bevacizumab may be delivered into the anterior chamber after subconjunctival administration and its pharmacokinetics in aqueous humor.The right eye of 33 rabbits received subconjunctival injection of 2.5 mg of subconjunctival bevacizumab. Three rabbits were sacrificed at each of the following time points: 0.5, 1, 2, 4, 8, 12, 24,
Moon Jung, Kim +3 more
openaire +3 more sources
Related searches:
Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium
Current Eye Research, 2008We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia.The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before ...
Irit Bahar, Igor Kaiserman
exaly +3 more sources
Subconjunctival Bevacizumab Injection for Corneal Neovascularization
Cornea, 2008To report on the clinical use of subconjunctival bevacizumab in patients with corneal neovascularization.The charts of 10 consecutive patients with corneal neovascularization who received subconjunctival injections of bevacizumab (2.5 mg/0.1 mL) were reviewed.
Irit Bahar, Igor Kaiserman
exaly +3 more sources
The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization
International Ophthalmology, 2013To evaluate the effects of various doses of subconjunctival bevacizumab injections in the treatment of patients with corneal neovascularization. During the 6-month-follow-up, no significant ocular or systemic adverse events were observed related to the subconjunctival bevacizumab injection.
Suphi Acar
exaly +3 more sources
To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy.A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy.
Hsiao-Sang, Chu +6 more
openaire +3 more sources
The purpose of this study was to evaluate the efficacy and safety of subconjunctival and corneal intrastromal bevacizumab injections on corneal neovascularization in patients with lipid keratopathy.Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal ...
Joo Youn, Oh +2 more
openaire +3 more sources

